Day: August 5, 2021

HighlightsRestructuring of Mkango and Talaxis’ interests in both the Songwe Hill Rare Earths Project and Maginito simplifies and optimises the Company’s ownership structure prior to delivery of the Songwe Hill Feasibility Study, and significantly enhances its growth potential:Mkango to increase ownership of the Songwe Hill Rare Earths Project and of Maginito to 100% in a £13m share transaction with Talaxis Mkango retains all offtake rights relating to Songwe Hill, Maginito and the 100% owned Pulawy Separation Plant project in PolandComplementary £5.52m fundraising at a 2.9% premium to its five-day VWAP, including a £700,000 investment by Non-Executive Chairman Derek Linfield Mkango is fully funded to complete the Feasibility Study for the Songwe Hill Rare Earths Project, targeted for completion in Q1 2022 Mkango now positioned...

Study will assess the benefit of combining UV1 with standard of care pembrolizumab Topline data expected in 2023Oslo, 5 August 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in FOCUS, an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the Company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab. FOCUS is one of Ultimovacs’ four Phase II trials of UV1 in combination with various immunotherapy agents across four different cancer indications. The primary endpoint of FOCUS is progression-free survival rate at 6 months, with readout of topline results expected in 2023. “Initiation of recruitment in FOCUS adds further momentum to...

In an effort to strengthen the management efficiency of Akropolis Group, the company that owns and manages shopping and entertainment centres in Lithuania and Latvia, an audit committee has been established by the decision of Vilniaus Prekyba, the company’s sole shareholder. Three persons – Eglė Čiužaitė and Šarūnas Radavičius as two independent members, and Vilniaus Prekyba’s financial controller Lukas Bendoraitis – were appointed as members of the Audit Committee for a term of four years. In addition, Mr Radavičius was elected Chairman of the Audit Committee. The decision to establish an audit committee for Akropolis Group was taken with the aim to further improve the business transparency and efficiency of the leading Baltic shopping centre development and management company, and to make sure that the financial and operating decisions...

HighlightsGAAP net income attributable to the partners and preferred unitholders of $53.3 million and GAAP net income per common unit of $0.53 in the second quarter of 2021. Adjusted net income(1) attributable to the partners and preferred unitholders of $57.0 million and adjusted net income per common unit of $0.57 in the second quarter of 2021 (excluding other items listed in Appendix A to this release). Total adjusted EBITDA(1) of $183.5 million in the second quarter of 2021. The Partnership’s LNG fleet is 98 percent fixed for the remainder of 2021, and 89 percent fixed for 2022. Current strong LNG shipping fundamentals expected to persist into 2022.HAMILTON, Bermuda, Aug. 05, 2021 (GLOBE NEWSWIRE) — Teekay GP L.L.C., the general partner (the General Partner) of Teekay LNG Partners L.P. (Teekay LNG or the Partnership) (NYSE:...

HighlightsReported GAAP net loss of $129.1 million, or $3.83 per share; and adjusted net loss(1) of $41.5 million, or $1.23 per share, in the second quarter of 2021 (excluding $86.7 million of vessel write-downs and other items listed in Appendix A to this release). In May 2021, Teekay Tankers repurchased two vessels with $57 million of existing liquidity that were previously under higher-cost sale-leaseback financings and therefore are currently unencumbered. Six additional vessels under similar sale-leaseback financings are scheduled to be repurchased in September 2021. Teekay Tankers has signed term sheets to refinance the above-mentioned vessels with lower-cost sale-leaseback financings, which are expected to be completed in the third quarter of 2021. Counter-cyclically in-chartered three Aframax-sized vessels for periods of 18 to...

HighlightsGAAP net loss attributable to shareholders of Teekay of $1.8 million, or $0.02 per share, and adjusted net income attributable to shareholders of Teekay(1) of $30 thousand in the second quarter of 2021 (excluding items listed in Appendix A to this release). Total adjusted EBITDA(1) of $171.9 million in the second quarter of 2021. Teekay Parent reduced its asset retirement obligation (ARO) associated with the Banff FPSO by approximately $33 million in the second quarter of 2021. Teekay LNG’s LNG fleet is 98 percent fixed for the remainder of 2021 and 89 percent fixed for 2022. Teekay Tankers counter-cyclically in-chartered three Aframax-sized vessels for periods of 18 to 24 months, plus extension options.HAMILTON, Bermuda, Aug. 05, 2021 (GLOBE NEWSWIRE) — Teekay Corporation (Teekay or the Company) (NYSE:TK) today reported...

All five drill holes completed to date have intersected significant widths of veining and sulphides demonstrating the robust nature of this mineralized system at the Surebet Polymetallic Gold-Silver Zone. Rush assays are expected in the immediate future for GD21-001. A second drill has been added to the 2021 Maiden Drill program based on mineralization observations of the polymetallic mineralization. Drilling is complete at the Cliff Showing with 865 meters in 5 drill holes. The drill has now moved to the North Zone drill pad located ~600 meters north of the Cliff Showing for the first (GD21-006) of several drill holes testing additional along-strike and up-dip extent. The final drill hole from the Cliff Showing drill pad, GD21-005 (123 meters, 340⁰/-45⁰) was drilled shallowly towards the north and intersected 27.8 meters* of quartz-sulphide...

ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update. “During the second quarter, we continued steady progress on patient recruitment in our Phase 3 ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) clinical program,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “Patient enrollment in both ENHANCE-1 and ENHANCE-2 continues across our international...

VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery system technology. The Company is excited to announce information regarding the status and timing of its breakthrough psilocybin technology that was presented by Dr. Robert E.W. Hancock, Executive Chairman during its August 4, 2021, Virtual Town Hall. Patent is Ready “We already have a patent written, we could file it today, but we are holding on filing the patent until we have worked through all of the possible...